Meridian Bioscience Inc. (VIVO): Price and Financial Metrics


Meridian Bioscience Inc. (VIVO): $26.07

0.78 (+3.08%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

VIVO POWR Grades


  • Quality is the dimension where VIVO ranks best; there it ranks ahead of 87.15% of US stocks.
  • The strongest trend for VIVO is in Growth, which has been heading down over the past 179 days.
  • VIVO ranks lowest in Growth; there it ranks in the 15th percentile.

VIVO Stock Summary

  • Meridian Bioscience Inc's stock had its IPO on February 26, 1992, making it an older stock than 81.81% of US equities in our set.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.37 for Meridian Bioscience Inc; that's greater than it is for only 20.62% of US stocks.
  • With a year-over-year growth in debt of -19.6%, Meridian Bioscience Inc's debt growth rate surpasses only 20.13% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to Meridian Bioscience Inc, a group of peers worth examining would be NSSC, SUPN, BKYI, KVHI, and IRIX.
  • VIVO's SEC filings can be seen here. And to visit Meridian Bioscience Inc's official web site, go to www.meridianbioscience.com.

VIVO Valuation Summary

  • VIVO's price/sales ratio is 2.9; this is 74.45% lower than that of the median Healthcare stock.
  • VIVO's price/earnings ratio has moved up 21.3 over the prior 243 months.
  • Over the past 243 months, VIVO's EV/EBIT ratio has gone up 16.9.

Below are key valuation metrics over time for VIVO.

Stock Date P/S P/B P/E EV/EBIT
VIVO 2021-08-31 2.9 2.7 12.3 9.5
VIVO 2021-08-30 2.9 2.7 12.4 9.5
VIVO 2021-08-27 2.8 2.7 12.2 9.4
VIVO 2021-08-26 2.7 2.6 11.8 9.1
VIVO 2021-08-25 2.8 2.6 11.9 9.2
VIVO 2021-08-24 2.8 2.6 11.9 9.1

VIVO Growth Metrics

    Its 2 year revenue growth rate is now at -2.19%.
  • Its 3 year cash and equivalents growth rate is now at 34.34%.
  • Its 2 year net income to common stockholders growth rate is now at 21.71%.
Over the past 52 months, VIVO's revenue has gone up $112,549,000.

The table below shows VIVO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 313.32 77.299 59.968
2021-09-30 317.896 66.865 71.407
2021-06-30 305.845 68.682 71.243
2021-03-31 327.131 73.752 87.081
2020-12-31 299.163 67.809 70.138
2020-09-30 253.667 47.976 46.186

VIVO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VIVO has a Quality Grade of B, ranking ahead of 84.82% of graded US stocks.
  • VIVO's asset turnover comes in at 0.713 -- ranking 41st of 682 Pharmaceutical Products stocks.
  • CPRX, CHRS, and XTNT are the stocks whose asset turnover ratios are most correlated with VIVO.

The table below shows VIVO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.713 0.637 0.468
2021-03-31 0.775 0.653 0.560
2020-12-31 0.763 0.636 0.495
2020-09-30 0.685 0.616 0.342
2020-06-30 0.686 0.611 0.339
2020-03-31 0.625 0.585 0.192

VIVO Price Target

For more insight on analysts targets of VIVO, see our VIVO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $26.00 Average Broker Recommendation 1.17 (Strong Buy)

VIVO Stock Price Chart Interactive Chart >

Price chart for VIVO

VIVO Price/Volume Stats

Current price $26.07 52-week high $28.72
Prev. close $25.29 52-week low $17.00
Day low $25.33 Volume 325,300
Day high $26.39 Avg. volume 446,025
50-day MA $26.02 Dividend yield N/A
200-day MA $21.93 Market Cap 1.14B

Meridian Bioscience Inc. (VIVO) Company Bio


Meridian Biosciences is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. The company was founded in 1976 and is based in Cincinnati, Ohio.


VIVO Latest News Stream


Event/Time News Detail
Loading, please wait...

VIVO Latest Social Stream


Loading social stream, please wait...

View Full VIVO Social Stream

Latest VIVO News From Around the Web

Below are the latest news stories about Meridian Bioscience Inc that investors may wish to consider to help them evaluate VIVO as an investment opportunity.

Meridian Bioscience Names Andy Kitzmiller as Chief Financial Officer

Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that Andy Kitzmiller joined Meridian Bioscience as Executive Vice President and Chief Financial Officer, reporting directly to CEO Jack Kenny. He will oversee the global finance organization and financial activities, including accounting and controllership, financial planning and analysis, tax, internal audit, and treasury.

Yahoo | February 21, 2022

Magellan Diagnostics Resumes Distribution of LeadCare® II Test Kits

Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that Magellan Diagnostics resumed manufacturing and distribution of their LeadCare® II test kits.

Yahoo | February 16, 2022

Meridian Bioscience (NASDAQ:VIVO) stock performs better than its underlying earnings growth over last five years

The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...

Yahoo | February 10, 2022

Will Meridian Bioscience (VIVO) Gain on Rising Earnings Estimates?

Meridian Bioscience (VIVO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Yahoo | February 8, 2022

Meridian Bioscience, Inc.'s (VIVO) CEO Jack Kenny on Q1 2022 Results - Earnings Call Transcript

Meridian Bioscience, Inc. (VIVO) Q1 2022 Earnings Conference Call February 4, 2022 10:00 A.M. ET Company Participants Charlie Wood - Vice President, Investor Relations Jack Kenny - Chief Executive Officer Julie Smith - Senior Vice President Controller & Principal Accounting Officer Conference Call Participants Yi Chen - H.C. Wainwright Presentation...

SA Transcripts on Seeking Alpha | February 4, 2022

Read More 'VIVO' Stories Here

VIVO Price Returns

1-mo -5.68%
3-mo 5.38%
6-mo 20.64%
1-year 32.34%
3-year 130.71%
5-year 102.97%
YTD 27.79%
2021 9.15%
2020 91.30%
2019 -43.29%
2018 28.02%
2017 -18.01%

Continue Researching VIVO

Want to see what other sources are saying about Meridian Bioscience Inc's financials and stock price? Try the links below:

Meridian Bioscience Inc (VIVO) Stock Price | Nasdaq
Meridian Bioscience Inc (VIVO) Stock Quote, History and News - Yahoo Finance
Meridian Bioscience Inc (VIVO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7499 seconds.